Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline
The DOI matches its Crossref record; 415 of the 415 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The objective of this document is to generate a practice guideline for the management and treatment of symptoms of the menopause. PARTICIPANTS: The Treatment of Symptoms of the Menopause Task Force included six experts, a methodologist, and a medical writer, all appointed by The Endocrine Society. EVIDENCE: The Task Force developed this evidenced-based guideline using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to describe the strength of recommendations and the quality of evidence. The Task Force commissioned three systematic reviews of published data and considered several other existing meta-analyses and trials. CONSENSUS PROCESS: Multiple e-mail communications, conference calls, and one face-to-face meeting determined consensus. Committees of The Endocrine Society, representatives from endorsing societies, and members of The Endocrine Society reviewed and commented on the drafts of the guidelines. The Australasian Menopause Society, the British Menopause Society, European Menopause and Andropause Society, the European Society of Endocrinology, and the International Menopause Society (co-sponsors of the guideline) reviewed and commented on the draft. CONCLUSIONS: Menopausal hormone therapy (MHT) is the most effective treatment for vasomotor symptoms and other symptoms of the climacteric. Benefits may exceed risks for the majority of symptomatic postmenopausal women who are under age 60 or under 10 years since the onset of menopause. Health care professionals should individualize therapy based on clinical factors and patient preference. They should screen women before initiating MHT for cardiovascular and breast cancer risk and recommend the most appropriate therapy depending on risk/benefit considerations. Current evidence does not justify the use of MHT to prevent coronary heart disease, breast cancer, or dementia. Other options are available for those with vasomotor symptoms who prefer not to use MHT or who have contraindications because these patients should not use MHT. Low-dose vaginal estrogen and ospemifene provide effective therapy for the genitourinary syndrome of menopause, and vaginal moisturizers and lubricants are available for those not choosing hormonal therapy. All postmenopausal women should embrace appropriate lifestyle measures.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Studies have not associated HRT in women 40-49 years with increased risk of breast cancer (161), and there is no evidence that estrogen replacement in women with premature ovarian failure relates to a higher risk of breast cancer ( 162).”
From Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline (2016) · cites this paper as [162]
Citations
Cites
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889 · cited 3×
“(MPA) in women with a uterus (18), was associated with risks disproportionate to preventive benefits (17, 18).”
Background2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.019 · Cited by 12,536
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 1×
“The Task Force followed the approach recommended by the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) group, an international group with expertise in development and implementation of evidence-based guidelines (1).”
Method2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk
Goff, D. C., Lloyd-Jones, D. M., Bennett, G., Coady, S., D’Agostino, R. B., Gibbons, R., Greenland, P., Lackland, D. T., Levy, D., O’Donnell, C. J., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.005 · Cited by 4,945
(2004) · JAMA · doi:10.1001/jama.291.14.1701 · Cited by 4,534 · cited 2×
“(MPA) in women with a uterus (18), was associated with risks disproportionate to preventive benefits (17, 18).”
BackgroundClinician’s Guide to Prevention and Treatment of Osteoporosis
Cosman, F., de Beur, S. J., LeBoff, M. S., Lewiecki, E. M., Tanner, B., Randall, S., & Lindsay, R. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2794-2 · Cited by 4,149 · cited 2×
“Recent guidelines address bonespecific therapies (43).”
BackgroundWriting Group Members, Rosamond, W., Flegal, K., Furie, K., Go, A., Greenlund, K., Haase, N., Hailpern, S. M., Ho, M., Howard, V., et al. (2008) · Circulation · doi:10.1161/circulationaha.107.187998 · Cited by 3,711
Breast cancer and hormone-replacement therapy in the Million Women Study
(2003) · The Lancet · doi:10.1016/s0140-6736(03)14065-2 · Cited by 2,993
Systematic review and meta-analysis
(2019) · Providing Information for Health · doi:10.1201/9781315377315-19 · Cited by 2,659
Cited by
Items 301–400 of 883
Piróg, M. M., Jach, R., & Undas, A. (2017) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2017.08.023 · Cited by 12
Syndrome génito-urinaire de la ménopause (SGUM). RPC les femmes ménopausées du CNGOF et du GEMVi
Hocké, C., Diaz, M., Bernard, V., Frantz, S., Lambert, M., Mathieu, C., & Grellety-Cherbero, M. (2021) · Gynécologie Obstétrique Fertilité & Sénologie · doi:10.1016/j.gofs.2021.03.025 · Cited by 17
Association between Reproductive Factors and Type 2 Diabetes: A Cross-Sectional Study
Yu, Y., Li, J., Jiang, Y., Zaid, M., Zhao, Q., Wang, N., Liu, X., Qiu, Y., Zhu, J., Tong, X., et al. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19021019 · Cited by 14
“Unfortunately, the menopausal transition is associated with high mortality and an increased risk of metabolic syndrome, cardiovascular disease, and osteoporosis [9,10,13,14].”
BackgroundDeng, Y., Huang, H., Shi, J., & Jin, H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911892 · Cited by 16
“The commonly used MHT therapies were classified into estrogen treatment (ET) and estrogen plus progestogens treatment (EPT) [6,7].”
MethodEmaminia, F., Rezaei, A., Badehnoosh, B., Ramezani, R., & Shabani, M. (2019) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2019.112229 · Cited by 16
“Natural menopause occurs in women's lives when menstrual periods stop permanently and the function of ovarian follicleceases (Stuenkel et al., 2015).”
BackgroundChallenges Faced by Women with Cystic Fibrosis
Jain, R., Kazmerski, T. M., Aitken, M. L., West, N. E., Wilson, A. W. M., Bozkanat, K. M., Montemayor, K., von Berg, K., Sjoberg, J., Poranski, M., et al. (2021) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2021.04.010 · Cited by 12
Nolan, B. J., Frydman, A. S., Leemaqz, S., Carroll, M., Grossmann, M., Zajac, J. D., & Cheung, A. S. (2022) · Endocrine Connections · doi:10.1530/ec-22-0170 · Cited by 15
Not time to abandon use of local vaginal hormone therapies
Pinkerton, J. V., Kaunitz, A. M., & Manson, J. E. (2018) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000001142 · Cited by 12
Self-citationDowlut-McElroy, T., & Shankar, R. K. (2022) · Journal of Pediatric and Adolescent Gynecology · doi:10.1016/j.jpag.2022.02.002 · Cited by 11
Menopausal hormone therapy for breast cancer patients: what is the current evidence?
Glynne, S., Simon, J. A., Branson, A., Payne, S. J., Newson, L. R., Manyonda, I., Cleator, S. J., Douek, M., USISKIN, S. I., Tobias, J. S., et al. (2025) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000002627 · Cited by 16
Adenoma Detection Rate in Average-Risk Population: An Observational Consecutive Retrospective Study
He, X., Lv, X., Zhang, B., Ying, X., Hu, C., Zhou, X., & Hu, J. (2023) · Cancer Control · doi:10.1177/10732748231193243 · Cited by 14
“Although previous studies 16,17 have con fi rmed that postmenopausal estrogen and progesterone replacement therapy can reduce the risk of CRC, whether menopause increases the incidence of colorectal adenomas remains unclear.”
Biomarkers and Social Determinants in Atherosclerotic Arterial Diseases: A Scoping Review
Scalise, E., Costa, D., Gallelli, G., Ielapi, N., Turchino, D., Accarino, G., Faga, T., Michael, A., Bracale, U. M., Andreucci, M., et al. (2025) · Annals of Vascular Surgery · doi:10.1016/j.avsg.2024.12.076 · Cited by 11
Bazedoxifene plus conjugated estrogen to treat menopausal depression—A pilot study
Kulkarni, J., Mu, E., Li, Q., Malicka, M., Gavrilidis, E., de Castella, A. R., & Gurvich, C. (2025) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2025.103527 · Cited by 12
Vesco, K. K., Leo, M. C., Bulkley, J. E., Beadle, K., Stoneburner, A. B., Francisco, M. C., & Clark, A. (2020) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2020.07.029 · Cited by 16
Irritable bowel syndrome in midlife women: a narrative review
Yang, P.-L., Heitkemper, M. M., & Kamp, K. (2021) · Women s Midlife Health · doi:10.1186/s40695-021-00064-5 · Cited by 16
“The use of low-dose menopausal hormone therapy may be an option in clinical practice to treat menopause symptoms including sleep disturbance [83].”
BackgroundKing, E. M., Kaida, A., Mayer, U., Albert, A., Gormley, R., de Pokomandy, A., Nicholson, V., Cardinal, C., Islam, S., Loutfy, M. R., et al. (2021) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000002897 · Cited by 11
Sexual dysfunctions and their treatment in liver diseases
Jagdish, R. K. (2022) · World Journal of Hepatology · doi:10.4254/wjh.v14.i8.1530 · Cited by 12
Menopause in people with cystic fibrosis
Prochownik, K., Jain, R., Taylor‐Cousar, J. L., Lavage, D. R., Stransky, O. M., Thomas, H. N., & Kazmerski, T. M. (2023) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000002155 · Cited by 11
The Impact of Hormonal Contraceptives on Breast Cancer Pathology
Dorchak, J., Maria, S., Guarinoni, J. L., Duensing, A. U., Somiari, S., Cavanaugh, J. E., Deyarmin, B., Hu, H., Iida, J., Shriver, C. D., et al. (2018) · Hormones and Cancer · doi:10.1007/s12672-018-0332-y · Cited by 11
Ryu, K.-J., Park, H., Kim, Y. J., Yi, K. W., Shin, J., Hur, J. Y., & Kim, T. (2018) · Maturitas · doi:10.1016/j.maturitas.2018.08.011 · Cited by 12
Adverse events during testosterone replacement therapy in 95 young hypogonadal thalassemic men.
Sanctis, V. D., Soliman, A. T., Daar, S., & Maio, S. D. (2019) · Acta bio-medica dell'Ateneo parmense/Acta biomedica · doi:10.23750/abm.v90i2.8477 · Cited by 12
Development and evaluation of an early menopause question prompt list
Yeganeh, L., Khan, N. N., Boyle, J. A., Gibson‐Helm, M. E., Teede, H. J., & Vincent, A. J. (2019) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000001429 · Cited by 13
Hypophysitis related to immune checkpoint inhibitors: An intriguing adverse event with many faces
Deligiorgi, M. V., Liapi, C. A., & Trafalis, D. T. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1869211 · Cited by 13
Hormone therapy and melanoma in women
Hill, M., Cartron, A. M., Burgoyne, M. E., & Driscoll, M. S. (2021) · International Journal of Women’s Dermatology · doi:10.1016/j.ijwd.2021.06.005 · Cited by 13
The Handbook of Wellness Medicine
Snellings, J. E. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108650182 · Cited by 12
L'Hermite, M. (2017) · Climacteric · doi:10.1080/13697137.2017.1285277 · Cited by 11
The management of women with menopausal disorders (review of clinical guidelines)
Yureneva, S. V., & Ermakova, E. I. (2017) · Russian Journal of Human Reproduction · doi:10.17116/repro2017235115-122 · Cited by 11
Zeng, Z., Jiang, X., Li, X., Wells, A. H., Luo, Y., & Neapolitan, R. E. (2018) · PLoS ONE · doi:10.1371/journal.pone.0197064 · Cited by 11
N-acetylcysteine with low-dose estrogen reduces cardiac ischemia-reperfusion injury
Sivasinprasasn, S., Palee, S., Chattipakorn, K., Jaiwongkum, T., Apaijai, N., Pratchayasakul, W., Chattipakorn, S. C., & Chattipakorn, N. (2019) · Journal of Endocrinology · doi:10.1530/joe-19-0108 · Cited by 11
Gerstl, B., Signorelli, C., Wakefield, C. E., Deans, R., Vaishnav, T., Johnston, K. A., Neville, K. A., Cohn, R. J., & Anazodo, A. C. (2023) · Journal of Cancer Survivorship · doi:10.1007/s11764-023-01349-6 · Cited by 10
“…development (precocious puberty, delayed or absent pubertal development) [8, 42, 43]; menstrual dysfunction [8, 44]; endocrine complications [8, 45–47]; sexual dysfunction disorders [1, 8, 48]; infertility [8, 49]; and obstetric and perinatal complications [8, 50–52] limits collaboration between…”
Climacteric and fibromyalgia: a review
Vidal-Neira, L. F., Neyro, J. L., Maldonado, G., Messina, O. D., Moreno-Alvarez, M., & Ríos, C. (2024) · Climacteric · doi:10.1080/13697137.2024.2376190 · Cited by 15
Fezolinetant effect on vasomotor symptoms due to menopause in women unsuitable for hormone therapy
Santoro, N. F., Neal-Perry, G., Stute, P., Blogg, M., Mancuso, S., Morga, A., Ottery, F. D., & Siddiqui, E. J. (2025) · Current Medical Research and Opinion · doi:10.1080/03007995.2025.2470752 · Cited by 16
Dunneram, Y., Chung, H., Cade, J. E., Greenwood, D. C., Dobson, A. J., Mitchell, E. S., Woods, N. F., Brunner, E. J., Yoshizawa, T., Anderson, D. J., et al. (2019) · European Journal of Clinical Nutrition · doi:10.1038/s41430-019-0398-9 · Cited by 10
Knowledge of genito-urinary syndrome of menopause among Italian gynecologists: the DIADEM survey
Alvisi, S., Baldassarre, M., Gava, G., Mancini, I., Cagnacci, A., Seracchioli, R., & Meriggiola, M. C. (2020) · Maturitas · doi:10.1016/j.maturitas.2020.09.011 · Cited by 10
Marsden, J. (2022) · Post Reproductive Health · doi:10.1177/20533691221122358 · Cited by 12
Neurokinin 3 receptor antagonists for menopausal vasomotor symptoms, an appraisal
Gompel, A., & Stuenkel, C. A. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101076 · Cited by 14
“These products are less efficacious than MHT.(9) A recent analysis comparing the efficacy of SSRI/SNRI and NK3R antagonists reported that SSRI/SNRI efficacy varies from 48% to 67% from baseline at weeks 8 or 12,(10) similar to reports with NK3R antagonists.”
ResultSelf-citationPrimary ovarian insufficiency: different approaches in three cases and a review of literature
Moreira, A. M., & Spritzer, P. M. (2016) · Endocrinology Diabetes and Metabolism Case Reports · doi:10.1530/edm-16-0026 · Cited by 10
de Oliveira, B. B. R., Coelho, C. G., Barreto, S. M., Giatti, L., & Araújo, L. F. (2022) · Cadernos de Saúde Pública · doi:10.1590/0102-311x00346520 · Cited by 13
Inayama, Y., Mizuno, K., Yamaguchi, K. D., Hamanishi, J., Takeuchi, M., Egawa, M., Mandai, M., & Kawakami, K. (2023) · Journal of obstetrics and gynaecology research · doi:10.1111/jog.15653 · Cited by 13
Fitoösztrogének a menopauza terápiájában
Remport, J., & Blázovics, A. (2017) · Orvosi Hetilap · doi:10.1556/650.2017.30805 · Cited by 15
Gouda, Z. A., Khalifa, M. E. A., Shalaby, S. M., & Hussein, S. (2017) · Biochemistry and Cell Biology · doi:10.1139/bcb-2017-0196 · Cited by 13
Vasomotor and Related Menopause Symptoms
Stuenkel, C. A. (2018) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0000000000000385 · Cited by 11
Self-citationThe relationship between menopausal hormone therapy and keratinocyte carcinoma: A review
Suresh, R., Twigg, A., & Murase, J. E. (2018) · International Journal of Women’s Dermatology · doi:10.1016/j.ijwd.2018.07.002 · Cited by 10
Stuenkel, C. A., & Santen, R. J. (2016) · Post Reproductive Health · doi:10.1177/2053369115626029 · Cited by 12
“On 7 October, of this year, the Endocrine Society published online its first clinical practice guideline for treatment of symptoms of the menopause.(1) This guideline builds upon our highly successful 2010 Scientific Statement on Postmenopausal Hormone Therapy.”
BackgroundSelf-citationAbouharb, A., Mehta, S., Rathnayake, H., & Pandit, H. G. (2023) · The Journal of Arthroplasty · doi:10.1016/j.arth.2023.08.061 · Cited by 13
Acquarulo, E. L., Hernandez, E., Kodzodziku, F., & Nemec, E. C. (2024) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000002301 · Cited by 10
Menopause misinformation is harming care
Christakis, M. K., Roebotham, T., Sterry, S., & Koshkina, O. (2025) · BMJ · doi:10.1136/bmj.r1695 · Cited by 11
Mahajan, S., Avad, P., & Langade, J. (2025) · International Journal of Women s Health · doi:10.2147/ijwh.s544267 · Cited by 13
Aging in women – The microbiome perspective
Ferrando, M. L., Busonero, F., Crobu, F., & Sanna, S. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102950 · Cited by 10
Ischemic Stroke in a Transgender Woman Receiving Estrogen Therapy
Kwan, P., & Pikula, A. (2019) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/cjn.2018.374 · Cited by 9
“According to the 2013 Endocrine Society guidelines for treatment of menopausal symptoms in women, HRT is contraindicated in women with a history of VTE, coronary artery disease, or previous stroke/transient ischemic attack (TIA).(4) The literature on estrogen therapy in transgender populations is less robust.”
MethodRole of menopausal hormone therapy in the prevention of postmenopausal osteoporosis
Zhao, N., Wei, W., Xu, Y., Li, D., Yin, B., & Gu, W. (2023) · Open Life Sciences · doi:10.1515/biol-2022-0759 · Cited by 18
Kapoor, E., Faubion, S. S., Hurt, R. T., Fischer, K. M., Schroeder, D. R., Fokken, S. C., & Croghan, I. T. (2020) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000001599 · Cited by 10
Zeydan, B., Lowe, V. J., Tosakulwong, N., Lesnick, T. G., Senjem, M. L., Jack, C. R., Fields, J. A., James, T. T., Gleason, C. E., Dowling, N. M., et al. (2021) · Neuroreport · doi:10.1097/wnr.0000000000001592 · Cited by 11
Kaminski, J., Mesa, C. O., Pavesi, H., Drobrzenski, B., & Amaral, G. D. (2021) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000001811 · Cited by 10
“per day) used in this study in conjunction with oral MP 100 mg daily have been recommended in recent guidelines for menopause treatment.(1,2,3)”
MethodKim, J.-E., Choi, J., Park, J., Shin, A., Choi, N., & Choi, J. (2021) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000001848 · Cited by 11
“Third, the number of events was insufficient, especially thrombotic events, which may have attributed to the nonsignificant associations of these disease outcomes with MHT. Fourth, the effect by a various range of years since menopause could not be considered in the current study because the number of women who starte…”
InfluentialRing, M. R. (2017) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2017.02.012 · Cited by 14
Piróg, M. M., Jach, R., & Kacalska‐Janssen, O. (2017) · Acta Obstetricia Et Gynecologica Scandinavica · doi:10.1111/aogs.13239 · Cited by 9
“Hormone therapy (HT) continues to be the most efficient treatment for climacteric symptoms (1,2).”
BackgroundMethodManaging Menopause by Combining Evidence With Clinical Judgment
SHUFELT, C. L., & Manson, J. E. (2018) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0000000000000378 · Cited by 9
Obesity in perimenopause — current treatment options based on pathogenetic factors
Porada, D., Gołacki, J., & Matyjaszek‐Matuszek, B. (2023) · Endokrynologia Polska · doi:10.5603/ep.96679 · Cited by 17
Xin, M. Q. L., & Lane, R. (2025) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000002498 · Cited by 8
From physiology to psychology: An integrative review of menopausal syndrome
Lang, X., Huang, C., Cui, H.-Y., Zhong, H., Shen, M.-Y., & Zhao, F. (2025) · World Journal of Psychiatry · doi:10.5498/wjp.v15.i11.108713 · Cited by 17
Then and Now: What We Have Learned From the WHI
Lambrinoudaki, I. V., Armeni, E., Mili, N., & Anagnostis, P. G. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf638 · Cited by 9
An individualized approach to the management of vaginal atrophy in Latin America
Palacios, S., Nappi, R. E., Marla Shapiro, C. M., de Melo, N. R., Wender, M. C. O., Fernandes, C. E., Pardini, D., Machado, R. B., Kulak, J., Celis-González, C., et al. (2019) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000001368 · Cited by 8
Hereditary Angioedema with and Without C1-Inhibitor Deficiency in Postmenopausal Women
Billebeau, A., Fain, O., Launay, D., Boccon‐Gibod, I., Bouillet, L., Gobert, D., Plu‐Bureau, G., & Gompel, A. (2020) · Journal of Clinical Immunology · doi:10.1007/s10875-020-00902-7 · Cited by 8
Self-citationWu, M., Lai, H., Deng, Q., Peng, X., Shen, J., Zhou, X., Peng, W., Zhu, L., Tu, H., & Li, X. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/3960834 · Cited by 11
“In addition, estrogen should be used in early prevention or treating PMOP before 60 years old or within 10 years after menopause, especially the patients with vasomotor syndrome (VMS).”
BackgroundCardiovascular Health and Healthy Aging
Reynolds, I. J., Page, R. L., II, & Boxer, R. S. (2019) · Springer eBooks · doi:10.1007/978-3-030-06200-2_5 · Cited by 12
Hypertension artérielle de la ménopause : dépister, traiter, accompagner, prévenir
Mounier‐Véhier, C., & Madika, A. (2019) · La Presse Médicale · doi:10.1016/j.lpm.2019.09.050 · Cited by 12
KASE, N. G., Friedman, E. G., & Brodman, M. L. (2020) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2020.06.008 · Cited by 9
Copsel, S. N., Malek, T. R., & Levy, R. B. (2020) · American Journal Of Pathology · doi:10.1016/j.ajpath.2020.07.012 · Cited by 10
Filho, A. L. D. S., Carvalho, G. M., de Sena, L. C., Gomes, L. P. G., Valério, M. F. H., Martins, R. I. L., & Cândido, E. B. (2020) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.66.8.1134 · Cited by 8
Kwon, H., Nguyen, Q. N., Na, M. W., Kim, K. H., Guo, Y., Yim, J. H., Shim, S. H., Kim, J., Kang, K. S., & Lee, D. (2021) · The Journal of Antibiotics · doi:10.1038/s41429-021-00473-8 · Cited by 8
“to treat these menopausal symptoms; [9] however, it has been linked to a high risk of various cancers in women including endometrial, breast, and ovarian cancers [10].”
BackgroundAssessment of estrogen exposure from transdermal estradiol gel therapy with a dried urine assay
Newman, M. S., Curran, D. A., Mayfield, B. P., Saltiel, D., & Stanczyk, F. Z. (2022) · Steroids · doi:10.1016/j.steroids.2022.109038 · Cited by 8
Rautenberg, T. A., Downes, M., Simoncini, T., Yu, Q., Ren, M., Wang, Y.-P., Custódio, M. G., & Kim, K. I. (2023) · Journal of Medical Economics · doi:10.1080/13696998.2023.2289297 · Cited by 10
Sheedy, A. N., Wactawski‐Wende, J., Hovey, K. M., & LaMonte, M. J. (2023) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000002272 · Cited by 12
Approach to Managing a Postmenopausal Patient
Santen, R. J., Heitjan, D. F., Gompel, A., Lumsden, M. A., Pinkerton, J. V., Davis, S. R., & Stuenkel, C. A. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa623 · Cited by 9
Self-citationAdvanced drug delivery technologies for postmenopausal effects
Md, S., & Kotta, S. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.07.038 · Cited by 10
Ovarian tissue cryopreservation and transplantation as a natural means to delay menopause
Saçıntı, K. G., Sadat, R., Özkavukçu, S., Sönmezer, M., & Sönmezer, M. (2024) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-024-07752-3 · Cited by 8
“HRT offers several benefits for managing menopausal symptoms and preventing long-term health consequences [59, 60].”
An, F., Jia, X., Shi, Y., Xiao, X., Yang, F., Su, J., Xia, P., Geng, G., & Yan, C. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113613 · Cited by 8
Is there a time limit for systemic menopausal hormone therapy?
Lipold, L. D., Batur, P., & Kagan, R. (2016) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.83a.15161 · Cited by 7
Lessons learned with Bone Health TeleECHO: making treatment decisions when guidelines conflict
Rothman, M. S., Olenginski, T. P., Stanciu, I., Krohn, K., & Lewiecki, E. M. (2019) · Osteoporosis International · doi:10.1007/s00198-019-05147-8 · Cited by 8
Preparation of Hop Estrogen-Active Material for Production of Food Supplements
Karabín, M., Haimannová, T., Fialová, K., Jelínek, L., & Dostálek, P. (2021) · Molecules · doi:10.3390/molecules26196065 · Cited by 7
“These symptoms are usually treated by hormone replacement therapy (HRT), involving the application of relatively high doses of hormones [26].”
BackgroundConsensus statement – Urogenital atrophy
Briggs, P. (2022) · Post Reproductive Health · doi:10.1177/20533691211065808 · Cited by 7
“Once the tissue quality has recovered, absorption of local estrogen decreases with minimal systemic effects and therefore smaller doses can be used to maintain the benefits achieved, hence a loading dose followed by a maintenance dose for most preparations.(12) It is important to inform women that although symptom con…”
BackgroundStrategies for Maintaining Brain Health: The Role of Stroke Risk Factors Unique to Elderly Women
Manwani, B., Finger, C. E., & Lisabeth, L. D. (2022) · Stroke · doi:10.1161/strokeaha.121.036894 · Cited by 10
Kwon, H., Roh, E., Ahn, C. H., Kim, H. K., Ku, C. R., Jung, K. Y., Lee, J. H., Kim, E. H., Suh, S., Hong, S., et al. (2022) · Endocrinology and Metabolism · doi:10.3803/enm.2022.1627 · Cited by 8
Pearson, A., Chen, J., Dhillon, H. M., & Kiely, B. E. (2024) · Breast Cancer Research and Treatment · doi:10.1007/s10549-024-07364-0 · Cited by 7
“International guidelines support use of vaginal oestrogens in women with BC, when non-hormonal interventions are unsuccessful in treating symptoms [14, 15].”
BackgroundHattersley, G., Harris, A. G., Simon, J. A., & Constantine, G. D. (2016) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000000726 · Cited by 7
“The specific objectives of this study were to (1) determine the effects of 28 days of treatment with RAD1901 on frequency”
BackgroundWilliams, B. R., & Cho, J. S. (2017) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2017.04.006 · Cited by 10
Literature Review: Menopause and Sexual Disorders
Siregar, M. F. G., Azmeila, S., Sitompul, A., & Siregar, M. E. A. G. (2021) · Open Access Macedonian Journal of Medical Sciences · doi:10.3889/oamjms.2021.6345 · Cited by 8
“Both are called a genitourinary syndrome, which combines the condition of VVA and urinary tract dysfunction [27] (Figure 5).”
BackgroundWhat should guide our patient management of vulvovaginal atrophy?
Marla Shapiro, C. M. (2018) · Climacteric · doi:10.1080/13697137.2018.1527306 · Cited by 7
Abordaje diagnóstico y terapéutico del síndrome genitourinario en la menopausia; Actualización.
Hoz, F. J. E. D. L., & Gallego, H. O. (2018) · Revista Médica de la Universidad de Costa Rica · doi:10.15517/rmucr.v11i2.34580 · Cited by 7
Yang, M., Jiang, L., & Yao, N.-N. (2022) · PubMed · doi:10.1097/gme.0000000000001899 · Cited by 7
“The selected CPGs also included those developed by other countries (n U 5).(23,31,32,34,35) The CPGs were produced by different groups, such as medical societies, 25,27-32,34-36 a government agency,(33) and an expert panel.”
BackgroundAlbayrak, G., Türk, A. Ç., & Özgül, S. (2024) · Maturitas · doi:10.1016/j.maturitas.2024.108149 · Cited by 7
Beyond hormones: 3PM approach to vaginal microbiota dynamics in postmenopausal women
Pongsupasamit, P., Thonusin, C., Luewan, S., Chattipakorn, N., & Chattipakorn, S. C. (2025) · The EPMA Journal · doi:10.1007/s13167-025-00406-7 · Cited by 9
Jeevananthan, A., Alexopoulos, A., Goldstein, K. M., & Moreno, A. C. (2025) · Journal of Women s Health · doi:10.1177/15409996251370925 · Cited by 8
“14,16,39 The lack of HT prescriptions by PCPs for POI shows a clear de fi - cit in guideline-based practice for primary care.”
Sulu, C., Gül, N., Tanrıkulu, S., Doğanşen, S. Ç., Öztürk, F. Y., Saraç, B., Ersungur, E. B., Aydın, E. T., Şahin, S., Özkaya, H. M., et al. (2023) · Pituitary · doi:10.1007/s11102-023-01342-3 · Cited by 6
Approach to the Patient: Hormonal Therapy in Transgender Adults With Complex Medical Histories
Iwamoto, S. J., Rothman, M. S., T'Sjoen, G. G., & Defreyne, J. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad536 · Cited by 8
Deshpande, N., & Rao, T. S. (2025) · Journal of Psychosexual Health · doi:10.1177/26318318251324577 · Cited by 7
Stanczyk, F. Z., & Vesper, H. W. (2025) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000002613 · Cited by 7
Chiaramonte, D. R., Ring, M. R., & Locke, A. (2017) · Medical Clinics of North America · doi:10.1016/j.mcna.2017.04.010 · Cited by 11
“Current guidelines support MHT in women without contraindications within 10 years of menopause and before age 60, especially when significant VMSs are present.(28,29) Chronic VMSs can negatively impact quality of life and reanalysis of data on MHT suggest a potential cardioprotective effect.”
BackgroundDo we have new preventive strategies for optimizing cardiovascular health in women?
Stuenkel, C. A. (2019) · Climacteric · doi:10.1080/13697137.2018.1561665 · Cited by 7
Self-citation
Metadata
- Authors
- Stuenkel, C. A., Davis, S. R., Gompel, A., Lumsden, M. A., Murad, M. H., Pinkerton, J. V., & Santen, R. J.
- Affiliations
- Mayo Clinic (US)
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2015-11
- Volume
- 100
- Issue
- 11
- Pages
- 3975-4011
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2162957019
- Cited by
- 884
- References
- 414
- Citations by year
- 2026: 79 · 2025: 96 · 2024: 66 · 2023: 69 · 2022: 82 · 2021: 96 · 2020: 121 · 2019: 89 · 2018: 75 · 2017: 57 · 2016: 47 · 2015: 4
- FWCI
- 52.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Sexual function and dysfunction studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Keywords
- menopause, hormone replacement therapy, vasomotor symptoms, climacteric, postmenopausal women, cardiovascular risk screening, breast cancer risk, ospemifene, vaginal estrogen, genitourinary syndrome of menopause, vaginal moisturizers, lifestyle intervention, personalized treatment
- MeSH terms
- Contraindications, Age Factors, Breast Neoplasms, Cardiovascular Diseases, Female, Humans, Menopause, Terminology as Topic, Risk Factors, Severity of Illness Index, Estrogen Replacement Therapy, Evidence-Based Medicine, Hot Flashes, Female Urogenital Diseases, Venous Thromboembolism, Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.